Skip to main content
SpringerLink
Log in

New Approaches in the Hormonal Therapy of Breast Cancer

  • Conference paper
Cancer Therapy

  • 75 Accesses

Abstract

Hormonal therapy plays a central role in the overall treatment strategy of sex-specific cancer. Long before the detection of hormones and hormone receptors, ablation of sex hormone glands became part of the treatment of breast and prostate cancer because, in spite of malignancy, the cell growth retained hormone dependence. Moreover, the demonstration of estrogen and/or progesterone receptors as a predictor for the effectiveness of hormonal manipulations in two-thirds to three- fourths of all breast cancers warranted further research in this field.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2:104–107, 162–165

    Google Scholar 

  2. Bonneterre J, Coppens H, Mauriac L, Metz M, Rouesse J, Armand JP, Fargeot P, Mathieu M, Tubiana M, Cappelaere P (1985) Aminoglutethimide in advanced breast cancer: Clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day. Europ J Cancer Clin Oncol 21: 1153–1158

    Article  PubMed  CAS  Google Scholar 

  3. Brodie AMH, Garrett WM, Tsai-Morris CH, Wink LC (1984) Aromatase inhibition: a new perspective in the treatment of breast cancer. In: Nagel G A, Santen RJ (eds) Aminoglutethimide as an aromatase inhibitor in the treatment of cancer. 13th International Congress of Chemotherapy, Vienna, Hans Huber, Berne, pp 11–23

    Google Scholar 

  4. Camacho AM, Brough AJ, Cash R, Wilroy RS (1966) Adrenal toxicity associated with the administration of an anticonvulsant drug. J Pediatr 68: 852–853

    Google Scholar 

  5. Cash R, Brough AJ, Cohen MNP, Satoh PS (1967) Aminoglutethimide as an inhibitor of adrenal steroidgenesis: mechanism of action and therapeutic trial. J Clin Endocrinol Metab 27: 1239–1248

    Article  PubMed  CAS  Google Scholar 

  6. Coombes RC, Goss PE, Dowsett M, Hutchinson G, Cunningham D, Jarman M, Brodie AMH (1987) 4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. Tumor Diag Ther 8: 271–273

    Google Scholar 

  7. Foekens JA, Henkelmann MS, Fukkink JF, Blankenstein MA, Klijn JGM (1986) Direct effects of LHRH analogs on tumor cells. Eur J Cancer (abstr III-s) 22: 725

    Google Scholar 

  8. Foekens JA, Henkelmann MS, Bolt-de Vries J, Portengen H, Fukkink JF, Blankenstein MA, van Steenbrugge GJ, Mulder E, Klijn JGM (1987) Direct effects of LHRH analogs on breast and prostatic tumor cells. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal manipulation of cancer: peptides, growth factors, and new (anti) steroidal agents. Raven, New York, pp 369-380 (Monograph series of the european organization for research on treatment of cancer [EORTC], vol 18 )

    Google Scholar 

  9. Gale KE (1982) Treatment of advanced breast cancer with aminoglutethimide. A 14-year experience. Cancer Res [suppl] 42: 3389s–3396s

    CAS  Google Scholar 

  10. Griffiths CT, Hall TC, Saba Z, Barlow JJ, Nevinny HB (1973) Preliminary trial of aminoglutethimide in breast cancer. Cancer 32: 31–37

    Article  PubMed  CAS  Google Scholar 

  11. Harris AL, Dowsett M, Smith IE, Jeffcoate SL (1983) Endocrine effects of low-dose aminoglutethimide alone in advanced postmenopausal breast cancer. Br J Cancer 47: 621–627

    Article  PubMed  CAS  Google Scholar 

  12. Harris AL, Powles TJ, Smith IE, Coombes RC, Ford HT, Gazet JC, Harmer CL, Morgan M, White M, Parsons CA, McKinna JA (1983) Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. Eur J Cancer Clin Oncol 29: 11–17

    Article  Google Scholar 

  13. Harvey HA, Lipton A, Santen RJ, Escher GC, Hardy MA, Glode LM, Sealoff A, Landau RL, Schneir H, Max DT (1981) Phase II study of a gonadotropin-releasing hormone analogue (Leuprolide) in postmenopausal advanced breast cancer patients. Proc Am Ass Cancer Res Am Soc Clin Oncol (Abstract C-436) 22: 444

    Google Scholar 

  14. Harvey HA, Lipton A, Max DT, Pearlman OHG, Diaz-Perches R, de la Garza J (1984) Effective medical castration produced by the GnRH analog Leuprolide in metastatic breast cancer. Proc Am Soc Clin Oncol (abstr C-435) 3: 111

    Google Scholar 

  15. Henderson IC, Cannelos GP (1980) Cancer of the breast. The past decade: Part 1. New Engl J Med 302: 17–30

    Article  PubMed  CAS  Google Scholar 

  16. Höffken K, Kempf H, Miller AA, Miller B, Schmidt CG, Faber P, Kley HK (1986) Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer. Cancer Treat Rep 70: 1153–1157

    PubMed  Google Scholar 

  17. Höffken K, Miller AA, Miller B, Becher R, Aulbert E, Hoffmann B, Anders CU, Callies R, Schmidt CG (1986) Niedrigdosierte Aminoglutethimid-Therapie ohne Cortisolsubstitution beim metastasierenden Mammakarzinom in der Postmenopause. Med Klin 81: 638–642

    Google Scholar 

  18. Höffken K, Jonat W, Possinger K, Kölbel M, Kunz T, Becher R, Callies R (1988) Aromatase inhibition with 4-hydroxyandrostenedione (4-OHA) in treatment of postmenopausal advanced breast cancer (BC). Verh Dtsch Krebsgesellschaft (to be published)

    Google Scholar 

  19. Höffken K, Oesterdickhoff C, Becher R, Callies R, Kurschel E, Anders CU, Scheulen ME, Schmidt CG (1989) LH-RH agonist treatment with Buserilin in premenopausal patients with advanced breast cancer: a phase II study. Cancer Ther Contr 1: (in press)

    Google Scholar 

  20. Hoogstraten B, Gad-el-Mawla N, Maloney TR, Fletcher WS, Vaughn CB, Tranum BL, Athens JW, Costanzi JJ, Foulkes M (1984) Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group Study. Cancer 54: 2248–2256

    Google Scholar 

  21. Ingle JN, Krook JE, Green SJ, Kubista TP, Everson LK, Ahmann DL, Chang MN, Bisel HF, Windschitl HE, Twito DI, Pfeifle DM (1986) Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4: 178–185

    PubMed  CAS  Google Scholar 

  22. Klijn JGM, de Jong FH (1982) Treatment with a luteinising hormone-releasing hormone ana-logue (Buserelin) in premenopausal patients with metastatic breast cancer. Lancet 1: 1213–1216

    CAS  Google Scholar 

  23. Klijn JGM, de Jong FH, Lamberts SWJ, Blankenstein MA (1985) LHRH-agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 23: 867–873

    CAS  Google Scholar 

  24. Klijn JGM, Paridaens R, Foekens JA (eds) (1987) Hormonal manipulation of cancer: peptides, growth factors, and new (anti) steroidal agents. Raven, New York, ( Monograph series of the european organization for research on treatment of cancer [EORTC]. vol 18 )

    Google Scholar 

  25. Klijn JGM, de Jong FH (1987) Long-term LHRH-agonist (Buserelin) treatment in metastatic premenopausal breast cancer. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal manipulation of cancer: peptides, growth factors, and new (anti) steroidal agents. Raven, New York, pp 343–352 (Monograph series of the european organization for research on treatment of cancer [EORTC], vol 18 )

    Google Scholar 

  26. Miller AA, Miller BE, Höffken K, Schmidt CG (1987) Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. Cancer Chemother Pharmacol 20: 337–341

    Article  PubMed  CAS  Google Scholar 

  27. Miller AA, Miller BE, Höffken K, Schmidt CG (1987) Conventional-dose aminoglutethimide without hydrocortisone replacement in patients with postmenopausal breast cancer: serum Cortisol levels and response to ACTH stimulation. J Exp Clin Cancer Res 16: 135–138

    Google Scholar 

  28. Murray R, Pitt P (1985) Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer. Eur J Cancer Clin Oncol 21: 19–22

    Article  PubMed  CAS  Google Scholar 

  29. Nicholson RI, Maynard PV (1979) Anti-tumour activity of ICI118630, a new potent luteinizing hormone-releasing hormone agonist. Br J Cancer 39: 268–273

    Article  PubMed  CAS  Google Scholar 

  30. Plowman PN, Nicholson RI, Walker KJ (1986) Remissions of metastatic breast cancer in post-menopausal women with luteinising hormone releasing hormone (ICI 118630) therapy. Eur J Cancer (abstract 111–18 ) 22: 746

    Google Scholar 

  31. Pritchard KI, Thomson DB, Myers RE, Sutherland DJA, Mobb BG, Meakin JW (1980) Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64: 787–796

    PubMed  CAS  Google Scholar 

  32. Santen RJ, Santner S, Davis B (1978) Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 47: 1257–1265

    Article  PubMed  CAS  Google Scholar 

  33. Santen RJ, Worgul TJ, Samojlike E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA (1981) A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305: 545–551

    Article  PubMed  CAS  Google Scholar 

  34. Schally AV, Redding TW, Comaru-Schally AM (1984) Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Cancer Treat Rep 68: 281–289

    PubMed  CAS  Google Scholar 

  35. Schinzinger AS (1889) Uber Carcinoma mammae. Zentralbl Chir [Suppl] 16: 55–56

    Google Scholar 

  36. Stuart-Harris RC, Smith IE (1984) Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev 11: 189–204

    Article  PubMed  CAS  Google Scholar 

  37. Stuart-Harris RC, Dowsett M, Bozek T, McKinna JA, Gazet JC, Jeffcoate SL, Kurkure A, Carr L, Smith IE (1984) Low-dose aminoglutethimide in treatment of advanced breast cancer. Lancet 2: 604–607

    Article  PubMed  CAS  Google Scholar 

  38. Waxman JH, Harland SJ, Coombes RC, Wrigley PFM, Malpas JS, Powles T, Lister TA (1985) The treatment of postmenopausal women with advanced breast cancer with Buserelin. Cancer Chemother Pharmacol 15: 171–173

    Article  PubMed  CAS  Google Scholar 

  39. Williams MR, Walker KJ, Turkes A, Blarney RW, Nicholson RI (1986) The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53: 629–636

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Clinic of Internal Medicine (Tumor Research), West German Tumor Center, Hufelandstraße 55, 4300, Essen 1, Germany

    K. Höffken

Authors
  1. K. Höffken
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of General Surgery, University of Ulm, Steinhövelstraße 9, 7900, Ulm, Germany

    Hans G. Beger FACS (Professor of Surgery) & Markus Büchler (Lecturer in Surgery) (Professor of Surgery) &  (Lecturer in Surgery)

  2. Division of Tumor Cell Biology, Scripps Clinic & Research Foundation, 10666 North Torrey Pines Road, 92037, La Jolla, CA, USA

    Ralph A. Reisfeld

  3. Clinical Research, Behringwerke AG Marburg, P.O. Box 1140, 3550, Marburg, Germany

    Gregor Schulz

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin · Heidelberg

About this paper

Cite this paper

Höffken, K. (1989). New Approaches in the Hormonal Therapy of Breast Cancer. In: Beger, H.G., Büchler, M., Reisfeld, R.A., Schulz, G. (eds) Cancer Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73721-3_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73721-3_33

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-73723-7

  • Online ISBN: 978-3-642-73721-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation